scholarly journals Vitamin K prophylaxis against haemorrhagic disease of the newborn in the United Kingdom.

BMJ ◽  
1991 ◽  
Vol 303 (6810) ◽  
pp. 1109-1109 ◽  
Author(s):  
J Handel ◽  
J H Tripp
1998 ◽  
Vol 47 (9) ◽  
pp. 889-892,897
Author(s):  
Takeshi YAMAGAMI ◽  
Seiji KOIKE ◽  
Takenori MARUYAMA ◽  
Isao NIIYA

PEDIATRICS ◽  
1994 ◽  
Vol 94 (1) ◽  
pp. 132-132
Author(s):  
Bruce Arroll ◽  
J. Thompson

We are writing to express our concerns about the recommendations of the Vitamin K Ad Hoc Task Force (Pediatrics 1993;91:1001-1002). Although we agree with some of their arguments, we feel that recommendation 3, which gives guidelines for using oral vitamin K, is both premature and unwarranted given the problems with the Golding et al1 paper. The design has numerous points for concern as does the interpretation because vitamin K in the United Kingdom contains three vehicles; any one of which could be the causative agent if indeed injected vitamin K does cause cancer.


2021 ◽  
Vol 21 (S1) ◽  
Author(s):  
Sophie Jullien

AbstractWe looked at existing recommendations and supporting evidence on the effectiveness of vitamin K given after birth in preventing the haemorrhagic disease of the newborn (HDN).We conducted a literature search up to the 10th of December 2019 by using key terms and manual search in selected sources. We summarized the recommendations and the strength of the recommendation when and as reported by the authors. We summarized the main findings of systematic reviews with the certainty of the evidence as reported.All newborns should receive vitamin K prophylaxis, as it has been proven that oral and intramuscular prophylactic vitamin K given after birth are effective for preventing classical HDN. There are no randomized trials looking at the efficacy of vitamin K supplement on late HDN. There are no randomized trials comparing the oral and intramuscular route of administration of prophylactic vitamin K in newborns. From older trials and surveillance data, it seems that there is no significant difference between the intramuscular and the oral regimens for preventing classical and late HDN, provided that the oral regimen is duly completed. Evidence assessing vitamin K prophylaxis in preterm infants is scarce.


2003 ◽  
Vol 89 (7) ◽  
pp. 1228-1231 ◽  
Author(s):  
N T Fear ◽  
◽  
E Roman ◽  
P Ansell ◽  
J Simpson ◽  
...  

The Lancet ◽  
1994 ◽  
Vol 343 (8893) ◽  
pp. 352 ◽  
Author(s):  
Rüdiger von Kries ◽  
Ulrich Göbel

2020 ◽  
Vol 11 ◽  
pp. 215013271989475
Author(s):  
Honey Thomas ◽  
Louise Smyth

Many patients are prescribed anticoagulants. Newer non–vitamin K oral anticoagulants, NOACs, were launched in 2008 and are increasingly commonly used. However, they may still be unfamiliar to patients and health care professionals. It is mandated by the National Patient Safety Agency and European Society of Cardiology to provide written safety information for patients receiving anticoagulants. We developed a standard patient alert card with the support of the North of England Strategic Clinical network (NESCN) to clearly provide key safety information for patients and health care professionals. This is the only card in the United Kingdom that is used over such a wide geographical area. We recognized that this would avoid duplication of work devising a similar card across all the sites in primary and secondary care. Given that staff and patients commonly move about the region it would also lead to better ease of recognition. The NESCN card was developed with input from all the key stakeholders, including cardiology, stroke, hematology, acute medicine, primary care, and patient groups. It was launched in 2015 across the Northern region, which includes over 3 million people. It was distributed to general practitioners (GPs), primary and secondary care pharmacists. Electronic and face-to-face education was carried out alongside to pharmacists, GPs, and hospital physicians. We gathered patient and clinical staff feedback regarding the card and found the alert card was widely embedded within practice across the region and patient feedback was good. The evaluation shows a simple and inexpensive intervention delivered with no formal funding can address this patient safety concern. We have engaged with Clinical Commissioning Groups and secondary care trusts in the region to ensure the legacy of the project. In response to requests from other regions and organizations, the card has been widely shared and implemented across many areas of the United Kingdom.


Sign in / Sign up

Export Citation Format

Share Document